ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL).

Laurie H. Sehn,Brad S. Kahl,Matthew J. Matasar,Georg Lenz,Koji Izutsu,Weili Zhao,Lin Tao,Roser Calvo,Pier Luigi Zinzani

ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL).

2021

Laurie H. Sehn
Brad S. Kahl
Matthew J. Matasar
Georg Lenz
Koji Izutsu
Weili Zhao
Lin Tao
Roser Calvo
Pier Luigi Zinzani

TPS7572Background: R-CHOP remains the standard of care for DLBCL. Although most patients (pts) can be cured, 3540% will experience relapsed/refractory disease, leading to poor outcomes in the majo...

Keywords:

Cyclophosphamide/doxorubicin/vincristine
Prednisone
Cancer research
Diffuse large B-cell lymphoma
Medicine
Germinal center
Rituximab
Acalabrutinib
Phases of clinical research
B cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations